Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspective
Stephen Chaplin(Vencore (United States)), Edward Li(Sanden (Japan)), Joris van Stiphout(Vencore (United States)), Anna Chen
Cited by 5
Related Papers
Synergistic Function of E2F7 and E2F8 Is Essential for Cell Survival and Embryonic Development
|Developmental Cell|2008|231
Inhibition of the mitochondrial pyruvate carrier protects from excitotoxic neuronal death
|The Journal of Cell Biology|2017|175
Characterizing the demographics of chronic pain patients in the state of Maine using the Maine all payer claims database
|BMC Public Health|2018|85
Projecting future drug expenditures—2012
|American Journal of Health-System Pharmacy|2012|81